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Background: Perioral	 dermatitis	 is	 a	 clinically	 distinctive	 reaction	pattern	of	 facial	










Results: The	 perioral	 dermatitis	 severity	 score	 decreased	 significantly	 during	 the	
treatment	period.	This	was	mirrored	by	significantly	 lower	patients’	subjective	nu‐
merical	rating	score	and	an	improved	quality	of	life	score.	Transepidermal	water	loss,	
stratum	 corneum	 hydration	 and	 skin	 erythema	 improved	 significantly	 during	 the	
treatment	period.
Conclusion: This	 transient	 receptor	 potential	 vanilloid	 type	 1	 inhibitor‐based	 skin	
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As	 none	 of	 the	 known	 treatment	 options	 seems	 optimal,	 and	














twice	 daily.	 The	 cream's	 ingredients	 are	water,	 squalene,	 glycerin,	
pentylene	glycol,	methylpropanediol,	 tapioca	starch,	arginine	HCL,	
cetearyl	 alcohol,	4‐t‐butylcyclohexanol	 (Trans‐Isomer),	 ammonium,	
acryloyldimethyl‐taurate/VP	 copolymer,	 sodium	carbomer	 and	 ca‐
prylyl	glycol.	Patients	were	not	allowed	to	use	any	other	topical	cos‐
metic	or	medicated	drug	on	the	face,	except	for	the	study	cream.
















firmness	 (depth	 of	 skin	 suction,	 in	mm)	 and	 elasticity	 (relationship	







Conference	 on	 Harmonized	 Tripartite	 Guidelines	 for	 Good	 Clinical	
Practice	1996,	Directive	91/507/EEC,	the	Rules	Governing	Medicinal	
Products	in	the	European	Community,	and	the	Declaration	of	Helsinki.























deviations.	 A	Wilcoxon	 signed‐rank	 test	with	 1‐tailed	P‐value	was	
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after	the	second	4	weeks.	All	three	PODSI	elements	showed	a	highly	
significant	 reduction	 over	 the	 course	 of	 8	 weeks	 as	 well;	 scaling	
showed	the	highest	reduction	(Figure	2).
The	 subjective	 aspects	 of	 POD	 also	 improved	 significantly	
during	 the	 trial	 period.	 The	 mean	 subjective	 disease	 severity	
on	a	 scale	 from	0	 to	10	 (NRS	10)	decreased	 from	6.74	±	1.93	 to	






TEWL	 remained	 unchanged	 in	 the	 first	 4	 weeks,	 changing	 from	
29.36	 ±	 11.98	 to	 29.21	 ±	 12.61	 (P	 =	 .3308),	 and	 then	 decreased	
to	 25.45	 ±	 9.98	 showing	 statistical	 significance	 (P	 =	 .0280)	 in	 the	
second	4	weeks.	The	most	statistically	significant	change	occurred	in	
the	stratum	corneum	hydration,	which	increased	in	the	first	4	weeks	











A	 correlation	 quotient	 R2	 =	 0.02271	 between	 the	 amount	 of	
cream	used	and	PODSI	improvement	was	determined	(Figure	5A),	
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without	 statistical	 significance.	 Another	 correlation	 was	 tested	
between	 POD	 duration	 and	 treatment	 response.	 A	 quotient	
R2	 =	 0.0002048	 was	 detected	 without	 statistical	 significance	
(Figure	5B).


























and	 expressed	 relief	 in	 the	 disease's	 psychological	 burden	 under	
therapy.	Other	POD	therapies	were	also	previously	established;	top‐
ical	erythromycin,	 topical	metronidazole,	and	systemic	 tetracycline	
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long‐term.	 Appropriate	 skin	 care	 can	 thus	 be	 used	 long‐term	 and	
serve	as	a	promising	topical	therapy	option	for	POD.













a	 skin‐soothing	 cream	 containing	 4‐t‐butylcyclohexanol	 functions	
simultaneously	 as	 a	psychological	 support	 and	a	biologically	 active	
therapy.	Instead	of	overhydrating	the	skin	and	re‐entering	the	hydra‐
tion‐dryness	vicious	circle,	physicians	should	develop	a	trustful	doc‐





ameliorating	 symptoms	 of	 POD	 patients	 is	 a	 substantial	 target	 of	
therapy	and	secondly,	the	subjective	disease	improvement	noted	by	
patients	leads	to	a	higher	compliance	and	remission	rate.
Influencing	 factors	 of	 treatment	 response	 were	 investigated	
by	 subgroup	 analysis.	 Patients	 with	 an	 atopic	 history	 responded	
significantly	 better	 to	 the	 treatment,	 whereas	 all	 other	 subgroup	
















in	 POD	 treatment.	 Objective,	 subjective	 POD	 scores	 and	 skin's	
physiological	parameters	clearly	improved	during	the	8‐week	treat‐
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